US Court Allows Investor Lawsuit Against Novo Nordisk
A US judge ruled that investors can sue Novo Nordisk over 2024 stock drops linked to weight-loss drug trials.
2026年8月2日
/ DANGDI / DANGDI / DANGDI /A US federal judge issued a new ruling against Novo Nordisk. Investors can move forward with a lawsuit against the company. The lawsuit concerns stock price drops in 2024. These drops followed trial results for its weight-loss drug CagriSema.
CagriSema is a key weight-loss drug made by the firm. Disclosures about its clinical trials caused stock price drops. Investors claim the company gave misleading information. The judge decided the case has merit to continue.
Novo Nordisk is based in Greater Copenhagen. It is the region's largest employer of foreign staff. Thousands of international researchers work at its local hubs. Developments here impact local industry confidence and hiring.
Many foreign professionals in Denmark track the company. Its financial health affects the broader Danish job market. For now, local operations in the capital region continue normally.
Source: The Copenhagen Post
